Ombudsman disagrees with EMA clinical trial data disclosure policy
This article was originally published in SRA
The European Ombudsman has criticised the European Medicines Agency for turning down requests for access to certain clinical trial data on two anti-obesity drugs – orlistat and rimonabant – on the grounds of protecting drug company commercial interests1,2.
You may also be interested in...
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.